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Case Report

Hemophagocytic Lymphohistiocytosis: A Series
of Five Clinical Cases in Adult Patients at a Single
Institution with a Review of the Literature
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Abstract
Context: Hemophagocytic Lymphohistiocytosis or the “Hemophagocytic Syndrome” is a spectrum of disorders of regulatory
immunomodulatory pathways inciting phagocytosis of hematopoietic cells resulting in end-organ damage. The condition appears in both
heritable and non-heritable forms from a multitude of possible environmental triggers, most notably infection. The condition often results
in a fatal outcome without prompt diagnosis and treatment. Cases in children have been reported much more frequently and classically
than in adult patients. Case Report: In this case series we examined five such cases in adult patients that were found at our institution in a
window as small at 2 years with more cases having presented since the time of this writing. In these cases, likely triggers were found ranging
from infectious, drug-inducing and even underlying malignancy. The condition can be diagnosed by a set of laboratory and physical criteria
(Hemophagocytic Lymphohistiocytosis -2004). Treatment ranges from immunosuppressive agents to chemotherapeutic approaches with
variable success. Conclusion: Clinicians must maintain a higher index of suspicion in cases presenting with ominous symptomatology to
ensure a prompt diagnosis and effective treatment of this potentially deadly condition.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a
spectrum of various conditions affecting regulatory
pathways. HLH is characterized by a constant activation
of CD8+ T lymphocytes and natural killer (NK) cells to
enact phagocytosis of hematopoietic cells and resulting in
organ damage, affecting mainly bone marrow, liver and
nervous system. The manifestations are often induced
by a preceding infectious process.[1,2] HLH is seen more
commonly among children with relatively fewer cases
diagnosed in adults. This is believed to be due somewhat
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to under-recognition. HLH contains two different
conditions that may be difficult to distinguish from one
another: A primary autosomal recessive form, familial
HL (FHL) and a secondary HLH (sHLH).[1,3] Prompt
diagnosis and treatment is essential to prevent a fatal
outcome. In this case series, we report on five distinct
cases of sHLH in adult patients arising from various
triggers. Laboratory trends were included in this writing
for informational purposes where available. All of these
cases occurred at our institution between the years 2012
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and 2014. As of this writing, we have continued to see
cases in additional patients.

Case Presentation
Case 1
A 24-year-old Hispanic female from the Dominican
Republic with past medical history of pregnancyinduced hypertension presented to our institution
with complaint of left-sided flank pain over the past
3 weeks. The pain was described as highly severe and
sharp. She also noticed a bump over the left side of her
back below the costovertebral angle. She visited the
emergency department twice during these 3 weeks
with conservative management and discharged home.
She complained of subjective fever, nausea, vomiting,
dysuria, dry cough and rash during the current visit.
She smokes 3 cigarettes per day and used to drink
alcohol many years ago but denied current use. On
presentation, vitals were temperature of 103.1 degrees,
a respiratory rate of 20 and heart rate of 142. On physical
exam, there was a macular rash noted on the left upper
chest, left back, both thighs and upper extremities with
no lymphadenopathy.
She continued to have fever spikes, and remained
tachycardic; her white blood cell (WBC) count remained
elevated with bandemia. Procalcitonin was elevated.
Laboratory values were trended as seen in Table 1.
Eventually the patient was transferred to intensive care
unit (ICU) for severe sepsis. The patient was found to
have bilateral axillary lymphadenopathy and cervical
lymphadenopathy, and on computed tomography (CT)
scan, left inguinal lymphadenopathy with increased
splenomegaly. Gallium scan was done, which showed

increased bone marrow uptake, suspicious for elevated
levels of serum iron. HLH was suspected but bone
marrow biopsy was not performed at that time as the
patient was too unstable.
Chemotherapy was started, including two doses of
Etoposide, Dexamethasone 20 mg IV daily for 2 weeks
and also intravenous immunoglobulin (IVIg) 30 gm IV
daily for 5 days. Soluble interleukin (IL)-II receptor assay
was 7867.00 pg/mL (reference range: 622 to 1619 pg/mL),
confirming the diagnosis. Bone marrow biopsy showed
normocellular bone marrow having increased numbers
of histiocytes with hemophagocytosis. HLH was thought
to be likely secondary to Still’s disease vs. viral infection
(Human herpes virus-6).
The patient became more stable and was started on
Cyclosporine 100 mg PO daily. Her condition continued
to improve and she was discharged home with a
diagnosis of HLH secondary to Still’s disease on PO
Cyclosporine, Dexamethasone and Bactrim. Patient
has good follow up with Hematology-Oncology and
Rheumatology clinic and was admitted in-patient twice
after this admission for exacerbation of Still’s disease. She
continues to do well with outpatient follow-up.

Case 2
A 33-year-old male also from the Dominican Republic
with no past medical history presented to our institution
with complaint of headache for 3 days, which was
generalized, 8/10 in severity at worst and associated
with nausea, vomiting, diarrhea, altered mental status
with difficulty finding words as per wife and also
multiple mosquito bites. The patient had just returned
from a trip to the Dominican Republic nine days prior.

Table 1: Laboratory Trends in Case 1
Day
WBC (4.5-11.0) K/mm
Hb (12.0-16.0) g/dL
Platelets (140-440) K/mm3
BUN (7-23) mg/dL
Creatinine (0.60-1.30) mg/dL
AST (13-39) U/L
ALT (7-52) U/L
ALP (34-104) IU/L
Ferritin (6.9-283.0) ng/mL
Triglycerides (<150) mg/dL
Total Protein (6.4-8.4) g/dL
Albumin (3.5-5.7) g/dL
Total Bilirubin (0.3-1.1) mG/dL
LDH (140—271) U/L
Lactic Acid (0.5- 2.2) mmol/L
Procalcitonin (<0.50) ng/mL
3
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1

2

6

11

14

20

23

18.5
12.4
197
7
0.81
73
20
65
—
—
7.4
3.6
0.40
—
0.7
—

14.2
10.6
176
5
0.61
—
—
—
4783
—
—
—
—
—
1.0
0.63

17.2
11.4
218
6
0.63
—
—
—
—
—
—
—
—
—
2.0
4.2

30.9
9.8
151
7
0.46
167
20
179
—
473
4.5
1.7
1.2
1634
1.2
7.12

20.9
10.0
174
38
0.74
367
67
138
>75,000
1436
5.6
1.9
1.1
2117
—
—

6.4
9.4
286
11
0.34
37
27
80
6748
157
5.9
2.5
1.4
470
—
—

3.7
9.2
209
—
—
—
—
—
1748
160
—
—
—
332
—
—

North American Journal of Medical Sciences | Sep 2015 | Volume 7 | Issue 9 |

[Downloaded free from http://www.najms.org on Friday, November 11, 2016, IP: 206.212.19.221]

Thomas, et al.: Hemophagocytic lymphohistiocytosis

On presentation, vitals included a temperature of
105 degrees, respiratory rate of 22, pulse 102, blood
pressure 135/78 and pulse oximetry of 99% on room
air. On physical exam, the patient had bibasilar rales,
was alert, awake and orientated to place and person
but not to time.
The patient was admitted after Dengue serology came
back positive. He had an episode of epistaxis and
hematemesis and continued to remain unstable and was
transferred to intensive care. Laboratory values were
trended as seen in Table 2. Bone marrow biopsy showed
normocellular bone marrow showing increased number
of histiocytes containing hemophagocytosed materials.
The diagnosis of HLH was made based on these findings
on consultation with the reading pathologist.
Chemotherapy was started the following day. Etoposide
with Dexamethasone along with plasmapheresis and
IVIg were included in the regimen. The patient also
received several units of blood products including single
donor platelets (SDP), fresh frozen plasma (FFP), packed
red blood cells (PRBCs) and cryoprecipitate. Despite
these measures, PT/INR and aPTT remained high.
The patient went into acute oliguric renal failure and
received hemodialysis. Patient continued to have spike in
temperature. He developed pancytopenia and was started
on Neupogen. On the ninth day of admission, the patient
had a seizure. He was made do not resuscitate (DNR) by
the family, went into asystole and passed away.

Case 3
A 58-year-old Caucasian male with past medical history
of hypertension, hypertriglyceridemia, chronic atrial
fibrillation, coronary artery disease (CAD) s/p coronary

artery bypass graft (CABG), ischemic cardiomyopathy
and past surgical history of pacemaker/defibrillator
placement presented to our institution with complaint of
shortness of breath for about a week prior to admission.
In the emergency room, the patient was noted to be
febrile. His heart rate and blood pressure, however,
were acceptable. On the chest X-ray, he was noted to
have bilateral infiltrates. He was hypoxemic on room
air. Lab reports were notable for thrombocytopenia
and leukopenia as well as marked elevation of his liver
transaminases and an elevated CPK level. Values are
trended in Table 3. The patient was started on noninvasive ventilation with BiPAP. The initial presumed
diagnosis was diffuse bacterial pneumonia. He was
started on broad spectrum antibiotic therapy.
The patient’s respiratory status continued to deteriorate
and he was intubated. Throughout the course of
hospitalization, spontaneous breathing and pupillary
responses were intact; however, his gag and cough
reflexes were absent. The patient was started on broad
spectrum antibiotics. He developed acute renal failure
early during hospitalization and hemodialysis was
started. He later developed hypotension requiring
the use of pressor medications. The patient remained
thrombocytopenic and although he had no evidence of
bleeding, platelets were transfused. He subsequently
developed gastrointestinal bleeding secondary to stress
ulceration as well as prior use of anti-platelet drugs and
thrombocytopenia. The patient received multiple units
of packed cells. Ferritin level was markedly elevated
at over 12,000 and viral-associated hemophagocytic
syndrome was suspected. Bone marrow biopsy was
performed, which showed mildly hypocellular bone
marrow showing mild increase in histiocytes with
hemophagocytosis.

Table 2: Laboratory trends in case 2
Day
WBC (4.5-11.0) K/mm
Hb (12.0-16.0) g/dL
Platelets (140-440) K/mm3
BUN (7-23) mg/dL
Creatinine (0.60–1.30) mg/dL
AST (13-39) U/L
ALT (7-52) U/L
ALP (34-104) IU/L
Ferritin (6.9-283.0) ng/mL
Triglycerides (<150) mg/dL
Total Protein (6.4-8.4) g/dL
Albumin (3.5-5.7) g/dL
Total Bilirubin (0.3-1.1) mG/dL
LDH (140-271) U/L
Lactic Acid (0.5-2.2) mmol/L
Procalcitonin (<0.50) ng/mL
3

1

2

3

4

9

10

4.5
14.9
29
11
1.14
874
358
60
> 15,000
175
6.8
3.7
0.9
1361
1.4
1.05

4.8
17.8
13
10
1.22
1807
655
63
59,666
194
7.0
3.9
1.5
3652
—
—

7.9
12.4
14
35
3.01
15,560
4100
56
84,367
132
6.6
3.1
4.0
14,100
—
—

7.5
8.9
21
52
5.36
19,416
4320
83
100,281
461
6.7
3.5
5.9
17,858
9.2
—

0.9
4.7
69
50
7.72
1242
262
83
10,100
180
4.5
3.1
13.5
—
6.6
7.20

1.2
8.1
63
50
8.05
—
—
—
14,325
420
—
—
—
4569
—
—
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Table 3: Laboratory trends in case 3
Day
WBC (4.5-11.0) K/mm3
Hb (12.0-16.0) g/dL
Platelets (140-440) K/mm3
BUN (7-23) mg/dL
Creatinine (0.60–1.30) mg/dL
AST (13-39) U/L
ALT (7-52) U/L
ALP (34-104) IU/L
Ferritin (6.9-283.0) ng/mL
Triglycerides (<150) mg/dL
Total protein (6.4-8.4) g/dL
Albumin (3.5-5.7) g/dL
Total bilirubin (0.3-1.1) mG/dL
LDH (140-271) U/L
Lactic acid (0.5-2.2) mmol/L
Procalcitonin (<0.50) ng/mL

1

3

1.8
13.9
55
41
1.50
—
—
—
—
—
—
—
—
—
2.3
2.23

3.3
14.3
60
35
1.20
1075
460
159
—
—
4.7
2.1
5.2
2310
—
2.56

5

9

6.4
10.5
12.6
6.7
31
41
99
95
4.20
3.50
437
85
225
69
98
56
12,019 2085
993
—
3.9
4.1
1.5
2.0
5.0
7.70
—
—
—
—
2.83
4.06

The patient’s condition continued to deteriorate.
In the second week, the patient developed massive
hemoptysis as well as bleeding from IV sites suggestive
of disseminated intravascular coagulation (DIC). Cardiac
arrest soon followed. Cardiopulmonary resuscitation
efforts were unsuccessful. The patient soon after expired.

Case 4
A 28-year-old Hispanic male presented to our institution
with a complaint of multiple intermittent episodes of
fever that began roughly 2 weeks prior to presentation
accompanied by profuse night sweats without rigors. The
patient was born in Mexico and has lived in the U. S. for
the past 13 years. He had not recently traveled outside
the U. S. He denied any contact with sick people, history
of transfusions, use of herbal medicines, and changes in
routine or eating habits. He had never experienced any
similar episodes in the past and reported being generally
healthy. He reported taking Ampicillin 500 mg tablets
for a total of six doses sporadically over the 2-week
period that was given to him by a friend. He also took
Acetaminophen as directed when needed. The patient
had fever with temperature 102.5 in the emergency
department. His initial physical examination was entirely
benign.
Rapid HIV, syphilis and Monospot tests were negative.
Levels were drawn for Acetaminophen and Salicylates,
which were both undetectable. The patient was subjected
to multiple viral, parasitic and bacterial testing, which
noted multiple past exposures but no acute source of
infection. Viral hepatitis profile was negative. Abdominal
ultrasound was unremarkable. Chest X-ray showed no
visual abnormalities of the heart and lungs. A CT of the
abdomen and pelvis without contrast was also obtained,
418

which noted no abnormalities. Liver biopsy was
performed, which showed non-specific inflammatory
changes. Lab tests were sent out for NK cell activity
and anti-CD25, which noted decreased NK activity,
establishing our diagnosis.
The patient received two doses of IVIg 900 mg and
was immediately started on antibiotic prophylaxis
with Cefepime 2 g, Vancomycin 1 g, and Doxycycline
100 mg every 12 hours. The patient was also placed on
Dexamethasone initially at 20 mg and tapered throughout
the stay. Cyclosporine 200 mg IV every 12 hours was
then initiated. Within 1 week of treatment, the patient
had remained afebrile for the majority of his stay and
improvements were noted in his laboratory values,
particularly with normalization of the aminotransferases
and bilirubin levels as well as in the ferritin and lactate
dehydrogenase. Triglycerides became elevated for a time
but began to normalize as treatment continued. There
was an appreciable improvement in his white blood cells
up to 0.9 109/L during admission without improvement
in neutrophil counts. The patient was subsequently
transfused a total of four units of PRBCs and discharged
on Cyclosporine 200 mg PO twice daily. At 1 week
follow-up, the counts had improved white blood cells
of 2.1 × 109/L with resolution of the neutropenia to
1.3 × 109/L and both LDH and ferritin levels had nearly
normalized. The patient had no recurrences of fever. He
presented again 3 months later. Initial laboratory values
noted blasts in peripheral blood. Bone marrow biopsy
was attempted multiple times but was unsuccessful.
Peripheral blood was then sent for flow cytometry
returning a diagnosis of acute lymphoblastic leukemia
(ALL). Given the lack of another triggering event, our
working hypothesis is that ALL itself was the trigger for
this patient’s HLH.

Case 5
A 43-year-old postmenopausal African American
women with a past history of breast cancer presented
to our institution with complaints of nausea, dizziness
and lightheadedness for 2 weeks. She also reported a
fever of 102 degrees, bleeding from the gums and some
difficulty breathing. She had previously been evaluated
and treated by us for her inflammatory breast cancer
and had been receiving a neoadjuvant chemotherapy
regimen prior to resection of the mass. Post-regimen,
her repeat positron emission tomography scan showed
worsening lymphadenopathy and the mass was deemed
unresectable. On physical exam in the emergency
department, it was noted that she had an abscess in the
right axilla. CT of the chest showed left axillary lymph
nodes, multiple lung metastases, small right pleural
effusion and diffuse liver metastases. Lab work showed
an elevated ferritin at 10,064 ng/mL. Ferritin levels were
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measured in an anemia profile at 10,064 ng/mL upon
admission. The patient was transfused with two units of
platelets for concurrent thrombocytopenia (29,000/mm3
and Vancomycin and Piperacillin/Tazobactam for the
abscess in her right axilla. The patient was transferred
to the ICU shortly after admission due to increased
lethargy, tachycardia with rate of 145. Vital signs at this
time included a temperature of 101.2 degrees, blood
pressure 91/52, with saturation 97% on 2 liters per
minute of Oxygen. Repeat blood work showed a white
blood cell count of 4,300/mm3, platelets 138,000/mm3.
Procalcitonin was 2.92. As per surgery, the right axillary
area was packed with gauze, which had a clean wound
base. Antibiotics were continued. Additionally, cancer
antigen 27-29 was measured at 128.9U/mL, LDH at
2258U/L and fibrinogen at 345 mg%. Ferritin levels rose
to 12,842 ng/mL from the previous day.
The following day, the patient had a temperature
of 100.3 degrees, pulse 121 and blood pressure of
106/90; she was placed on palliative care thereafter,
including pain management. An ultrasound of the
liver was done due to elevated AST 308U/L and
ALT 109U/L, which found hepatosplenomegaly
with multiple hepatic lesions. A bone scan showed
metastatic disease involving the right shoulder girdle,
upper sternum, thoracic and lumbar spine, pelvis
and right hip. LDH levels rose from 2,823 U/L to
3,072 U/L over the next 24 hours. During the same
time frame, ferritin levels rose from 15,000 ng/mL to
26,210 ng/mL; triglycerides had remained elevated at
232 mg/dL and 235 mg/dL, respectively. Considering
these laboratory values with the recent history of
fever and ultrasound showing hepatosplenomegaly,
the patient met the criteria for the diagnosis of HLH.
No biopsy of the bone marrow was taken during this
stay. The patient became nonverbal and confused.
Her care was discussed with her family. She was
made DNR and placed on a morphine drip. The
patient expired later the same day.

Discussion
We understand that HLH is a life-threatening disorder
of uncontrolled immune system activation, which can
have congenital or secondary forms. These can be seen
in both children as well as adults.[1,3] The congenital
form results from a range of genetic defects including
several associated gene mutations such as PRF1 on
10q21, UNC13D on 17q25 and LYST on 1q41.[3] sHLH
can develop as a result of strong immune system
activation as mentioned above which frequently arises
from infection, however our experience as well as other
literature has noted that they can arise from almost any
exogenous, rheumatic, or malignant process.[1-3] Both
primary and secondary cases of this disorder can also

be associated with several immunodeficiency syndromes
such as Chediak-Higashi, Griscelli and X-linked
lymphoproliferative syndrome with sporadic cases of
sHLH seen in association; however, secondary acquired
disease typically has no underlying syndromes.[3]
Diagnosis of this condition is based on clinical and
laboratory evidence based on a set of criteria known as
HLH-2004. This criteria is a revisal of initially agreedupon guidelines that were established in 1991.[4] Clinical
findings of fever, splenomegaly, cytopenia in at least two
lineages, hypertriglyceridemia and hypofibrinogenemia
with hemophagocytosis in the spleen or lymph nodes
also now include hyperferritinemia, low or absent
NK cell activity and elevated levels of sIL-2r with five
of the eight criteria being met in order to establish
diagnosis and those with molecular criteria bypassing
this requirement.[4] Research continues to study this
condition, and understanding of its pathophysiology
continues to improve. In one such study by Jenkins
et al., the role of sphingolipids was assessed. “Patients
with HLH exhibited elevated levels of serum S-SMase
activity, with concomitant elevations in several ceramide
species and sphingosine, while levels of sphingosine-1phosphate were significantly decreased. Importantly,
the ratio of C16-ceramide:sphingosine was uniquely
elevated in HLH patients that died despite appropriate
treatment, but remained low in HLH patients that
survived, suggesting that this ratio may be of prognostic
significance.”[5]
Treatment options remain limited but continue to
evolve. The HLH-94 protocol includes early and
aggressive management including ICU care as needed
and there remains a strong role for supportive measures
as well as chemotherapy including Etoposide and
Dexamethasone. [6] These two were chosen over
prednisone as central nervous system disease is relatively
common, particularly in children and thus crosses the
blood-brain barrier.[1,2] The proposed goal of therapy
was either remission of the condition or stability
until hematopoeitic stem cell transplant (HSCT) and
alternatively bone marrow transplant (BMT) could be
performed.[2,6] This was extensively studied in a trial
of 113 subjects by Henter et al., in 2002 just prior to the
revised HLH-2004 protocol where BMT followed HLH94 treatment with good survival outcomes.[6] The 2004
protocol introduced HSCT formally and it has been
noted that survival over that decade since the HLH-94
protocol in patients has improved. We understand the
risks of utilizing some of the drugs noted in the treatment
protocols for HLH and have tailored the treatments for
each patient in this series based on the severity of their
disease. As the 2007 study noted, this process is ongoing
as we attempt to better understand the pathophysiology;
participation in clinical trials by patients with HLH
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has been encouraged by these previous studies. [2]
Unfortunately there is still limited data on this condition
in adults and trials have been difficult due to lower
numbers of reported cases. Nearly all standard literature
reviewed involved predominantly pediatric populations.
One study in 2003 by Imashuku et al., looked at young
adult patients with sHLH triggered by the Epstein-Barr
virus (EBV). Patients who received Etoposide within
4 weeks of diagnosis had a good prognosis further
establishing this drug’s importance in the HLH treatment
protocols. This was also a study done on patients versus
a pediatric population, which noted nearly equivalent
efficacy.[7]

Financial support and sponsorship

Novel targets continue to be explored in HLH. Olin et al.,
investigated the use of anti-CD25 antibody daclizumab
in the treatment of HLH in an adult patient.[8] This
patient was EBV negative at diagnosis and first relapse.
The condition was initially treated with steroids and
immunosuppression with cyclosporine as was routinely
done with some of our cases; however, cyclosporine
had to be discontinued due to renal dysfunction
and hyperkalemia. Daclizumab was instituted in the
treatment of this patient with very promising results.[8]

3.

As cases of this disease in adult patient remains less
common than in the pediatric literature, due diligence
must be maintained to diagnose and treat these patients
aggressively to avoid organ damage and higher
likelihood of mortality. The cases we present here were
intended to add to the existing body of literature with
the intent to raise awareness of this condition in adults.
We suspect that it is likely that HLH continues to be
underreported and given the cluster of cases that we
have seen in our institution and with more numbers
being diagnosed the condition may very well be much
more common in adult patients than we think.
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